The increased dividend will add about $1.7 billion in value to the CVS deal, previously estimated at $24 billion. That brings it roughly into line with the Express Scripts bid worth about $26 billion. Caremark officials weren't immediately available for comment after the judge's ruling. Caremark shares rose $2.19, or 3.5 percent, to $63.19 on the New York Stock Exchange where CVS shares fell 39 cents, or 1.1 percent, to $32.10. Express Scripts stock rose 96 cents to $75.69 on the Nasdaq Stock Market. The other conditions of the CVS bid for Nashville-based Caremark remain unchanged, and the companies reiterated the benefits of the proposed deal, including annual cost savings and cash flow projections. The CVS offer has already won antitrust approval. But the offer from Express Scripts of Maryland Heights, Mo., has yet to receive antitrust clearance. Express Scripts is the third-largest pharmacy benefits manager and Caremark is No. 2.